Benitec Biopharma Inc. (BNTC)
14.17
-1.94 (-12.04%)
At close: Mar 24, 2025, 3:59 PM
14.77
4.23%
After-hours: Mar 24, 2025, 07:15 PM EDT
-12.04% (1D)
| Bid | 14.05 |
| Market Cap | 332.31M |
| Revenue (ttm) | 6.37K |
| Net Income (ttm) | -22.75M |
| EPS (ttm) | -0.62 |
| PE Ratio (ttm) | -22.85 |
| Forward PE | -1.14 |
| Analyst | Buy |
| Ask | 14.98 |
| Volume | 63,127 |
| Avg. Volume (20D) | 38,779 |
| Open | 16.51 |
| Previous Close | 16.11 |
| Day's Range | 14.05 - 16.51 |
| 52-Week Range | 4.75 - 16.90 |
| Beta | 0.92 |
About BNTC
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company w...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 24, 2014
Employees 16
Stock Exchange NASDAQ
Ticker Symbol BNTC
Website https://benitec.com
Analyst Forecast
According to 8 analyst ratings, the average rating for BNTC stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 62.31% from the latest price.
Stock Forecasts1 month ago
+15.98%
Benitec Biopharma shares are trading higher follow...
Unlock content with
Pro Subscription
10 months ago
-12.22%
Benitec Biopharma shares are trading lower after the company reported worse-than-expected Q3 GAAP EPS results and a year-over-year decrease in Q3 revenue results.
